Aberdeen, Scotland and Singapore (ots/PRNewswire) - - Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities - Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer's Disease (CTAD) conference ...
Aberdeen, Scotland and Singapore (ots/PRNewswire) - - Substantial investment of USD119 million achieved by TauRx through a warrants exercise triggered by the announcement of LUCIDITY results in October, supporting HMTM regulatory submissions in UK, US and Canada, and preparation for market availability - Shareholder ...
Aberdeen, Scotland and Singapore (ots/PRNewswire) - - Substantial investment of USD119 million achieved by TauRx through a warrants exercise triggered by the announcement of LUCIDITY results in October, supporting HMTM regulatory submissions in UK, US and Canada, and preparation for market availability - Shareholder ...
Aberdeen, Scotland and Singapore (ots/PRNewswire) - - Significant milestone in the only late-stage clinical trial targeting tau pathology of Alzheimer's - TauRx on track to announce top line results in May - Trial aims to confirm efficacy of first tau-based treatment for Alzheimer's TauRx Pharmaceuticals Ltd, a global leader in tau-based Alzheimer's Disease (AD) research, has announced that the last patient has completed ...
Aberdeen, Scotland and Singapore (ots/PRNewswire) - Minimum dose of hydromethylthionine could slow clinical decline and brain atrophy in behavioural variant Fronto-Temporal Dementia as well as Alzheimer's Disease In a paper published online in the Journal of Alzheimer's Disease ( https://doi.org/10.3233/JAD-191173 ) , TauRx reported that the drug it is developing for ...
Aberdeen, Scotland and Singapore (ots/PRNewswire) - Promising Read-Out for First-Ever Tau Aggregation Inhibitor to Enter Phase 3 Trials - LMTX® as monotherapy demonstrates significant reductions in disease progression in mild and moderate Alzheimer's disease - Strong results in both cognitive and functional tests supported by brain scan evidence of slow-down in progression of pathology - Study misses co-primary endpoints ...